未登录

N

Ningning Li

Peking Union Medical College Hospital

H指数:11

被引数:414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of the gut microbiome on response and toxicity to chemotherapy in advanced esophageal cancer

肠道菌群对晚期食管癌化疗反应和毒性的影响

IF3.6

2024-06-012

OAAI

First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

PRE

Prognostic and predictive significance of circulating biomarkers in patients with advanced upper gastrointestinal cancer undergoing systemic chemotherapy

循环生物标志物在晚期上消化道肿瘤全身化疗患者中的预后及预测意义

FRONTIERS IN ONCOLOGY

IF3.3

2023-06-065

OAAI

Clinical features and prognosis of lung cancer in patients with connective tissue diseases: a retrospective cohort study

FRONTIERS IN ONCOLOGY

IF3.3

2023-06-052

OAAI

Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer - updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C

ANNALS OF ONCOLOGY

IF65.4

2023-06-010

OA

Peripheral CD8+CD28+T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-03-1012

OAAI

The Relationship Between Gut Microbiome Features and Chemotherapy Response in Gastrointestinal Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2021-12-2334

OAAI

Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

IF3.4

2021-07-223

OAAI

Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma

ANNALS OF ONCOLOGY

IF65.4

2020-11-013

OAAI

Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI

Endometriosis-associated recto-sigmoid cancer: a case report

IF3.4

2018-09-2010

OAAI

Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma

CLINICAL EPIGENETICS

IF4.4

2018-04-0320

OAAI